10 Micro-, Small-Cap Firms Dominate Thursday’s Gains

6. Regencell Bioscience Holdings Ltd. (NASDAQ:RGC)

Regencell Bioscience soared to a new high on Friday, adding 46.25 percent to its valuation to end at $45 each following a share buyback program initiative.

Earlier this week, RGC announced that its chief executive officer, Yat-Gai Au, supported a share repurchase program and personally financed funds to finance the acquisition.

The initial transaction involved the buyback of 652,000 RGC shares from investment company Digital Mobile Venture at an average price of $9.5 apiece for a total of $6.19 million. Following the acquisition, Au owned a little over 11 million shares, representing 86 percent of the firm.

In the past four trading days alone, RGC’s shares were already up by 256 percent from the $12.62 closing price on Friday.

RGC is a biotech company that’s on a mission to commercialize traditional Chinese medicine for ADHD treatment, a subject that hits close to home for Au.